PROGRESS IN CARDIOVASCULAR DISEASES is a leading journal in the field of cardiology and cardiovascular medicine, published by W B SAUNDERS CO-ELSEVIER INC. With an impressive impact factor that places it in the esteemed Q1 quartile of its category, this journal ranks among the top 32 out of 387 journals in its field, positioning itself in the 91st percentile. Since its inception in 1958 and continuing until 2024, it has been a prolific source of cutting-edge research, reviews, and clinical insights that contribute significantly to the understanding and treatment of cardiovascular diseases. Although it does not currently offer open access options, the journal's rigorous peer-review process ensures that all published content meets the highest standards of scientific excellence. As a key resource for researchers, practitioners, and students alike, PROGRESS IN CARDIOVASCULAR DISEASES serves as an indispensable tool for advancing knowledge and practice in cardiovascular health.

TRENDS IN CARDIOVASCULAR MEDICINE, published by Elsevier Science London, stands at the forefront of the cardiology field, with a commendable Q1 ranking in the category of Cardiology and Cardiovascular Medicine. Since its inception in 1991, this esteemed journal has provided a vital platform for disseminating cutting-edge research and innovative clinical practices, reflecting the dynamic developments in cardiovascular health. With an impact factor positioning it among the top 3% in its category, TRENDS IN CARDIOVASCULAR MEDICINE is essential reading for researchers, healthcare professionals, and students pursuing the latest advancements and evidence-based approaches in cardiology. Although this journal does not currently operate under an open-access model, its rich array of content encompasses a variety of topics from clinical studies to reviews, ensuring readers stay informed on the pivotal trends that shape cardiovascular medicine. This commitment to excellence underscores the journal's role as a premier resource for anyone dedicated to improving cardiovascular health.

British Journal of Pharmacology is a premier, peer-reviewed journal published by Wiley, specializing in the dynamic field of pharmacology. With a robust impact factor, this journal ranks in the top quartile (Q1) for pharmacology according to the 2023 category rankings, emphasizing its significance and reputation among the global scientific community. As an essential resource for researchers, professionals, and students alike, the journal provides a platform for innovative research spanning foundational studies to clinical applications in pharmacology, toxicology, and pharmaceutics. Since its inception in 1966, the journal has consistently contributed to the advancement of pharmacological science, fostering a deeper understanding of drug action mechanisms and therapeutic advancements. Although primarily subscription-based, the British Journal of Pharmacology is committed to disseminating high-quality research that shapes the future of the field.

MOLECULAR PHARMACOLOGY, published by the American Society for Pharmacology and Experimental Therapeutics, is an influential peer-reviewed journal dedicated to advancing the field of pharmacology through comprehensive research on molecular mechanisms of drug action. With an impressive historic convergence from 1965 to 2024, this journal plays a pivotal role in disseminating high-quality research, showcasing significant findings that impact both clinical and experimental pharmacology. Notably, it holds a distinguished Q1 ranking in Pharmacology and a Q2 ranking in Molecular Medicine as of 2023, reflecting its prominence in the academic community. Researchers and practitioners engaged in pharmacological studies will benefit from the journal’s focus on new therapeutic strategies, drug development, and the molecular basis of drug action. While MOLECULAR PHARMACOLOGY is not an open-access journal, it offers a wealth of knowledge behind a subscription model, ensuring that contributors and readers maintain a high standard of academic rigor. Address all inquiries to the editorial office located at 9650 Rockville Pike, Bethesda, MD 20814-3995, United States.

CARDIOVASCULAR RESEARCH, published by Oxford University Press, is a premier academic journal dedicated to the evolving field of cardiology and cardiovascular medicine. With a remarkable impact factor reflecting its significant contribution to the scientific community, this journal maintains a Q1 ranking in both Cardiology and Physiology categories, demonstrating its commitment to publishing high-quality research that influences clinical practices and healthcare outcomes. Established in 1967, the journal has consistently provided a platform for innovative studies and reviews, aiming to advance our understanding of cardiovascular physiology and pathology. Researchers, professionals, and students will find published articles crucial for their work, as the journal covers a broad spectrum of topics including molecular biology, genetics, and clinical studies. While currently not offering open access options, CARDIOVASCULAR RESEARCH remains accessible through institutional and individual subscriptions, ensuring that the latest findings are available to those in the cardiovascular science community.

Welcome to the Journal of Cardiovascular Medicine, a leading platform for the dissemination of high-quality research in the field of cardiology and cardiovascular medicine. Published by Lippincott Williams & Wilkins, this esteemed journal boasts an ISSN of 1558-2027 and an E-ISSN of 1558-2035, reflecting its commitment to accessible and innovative cardiovascular research. With a significant impact factor and ranked Q2 in both Cardiology and Cardiovascular Medicine as well as in Medicine (Miscellaneous) for 2023, the journal is recognized for its contributions to advancing knowledge and practice in this critical area of health. The journal disseminates original research, reviews, and clinical studies, aimed at clinicians, researchers, and healthcare professionals who are dedicated to improving cardiovascular health outcomes. With a continuous commitment to evolving research from 2006 to 2024, the journal is an essential resource for those looking to stay at the forefront of the latest discoveries and methodologies in cardiovascular medicine.

Journal of Pharmacological Sciences is a leading peer-reviewed academic journal dedicated to the field of pharmacology, published by the Japanese Pharmacological Society. Since its inception, this journal has offered an essential platform for the dissemination of high-quality research, contributing significantly to advancements in molecular medicine and pharmacology. With an impact factor that places it in the prestigious Q2 quartile for both categories, the journal has established itself as a credible source of innovative findings and methodologies since its transition to Open Access in 2015. This accessibility enables a broader audience, including researchers, healthcare professionals, and students, to engage with valuable insights and discussions pertinent to drug development, pharmacodynamics, and therapeutic strategies. Based in Kyoto, Japan, the journal serves as a vital resource for the global pharmacological community, encouraging collaboration and research that leads to improved health outcomes. For more information, submissions, and access to the latest research, visit the journal’s website.

The European Journal of Preventive Cardiology, published by Oxford University Press, is a leading international journal dedicated to the field of cardiology and cardiovascular medicine. With an impact factor that underscores its prestige—ranking in the top quartile (Q1) of both cardiology and epidemiology categories—the journal serves as a critical resource for researchers and practitioners seeking to advance their understanding of preventive strategies in cardiovascular health. Since its inception in 1999, it has provided a platform for high-quality research and reviews that address the epidemiology of cardiovascular diseases, risk factor management, and innovative prevention methodologies. Notably, it currently ranks #21 out of 387 in Medicine - Cardiology and #13 out of 148 in Medicine - Epidemiology according to Scopus, highlighting its influential position in these essential biomedical fields. The journal also provides open access options, allowing both readers and authors the opportunity to engage with groundbreaking research and enhance the dissemination of knowledge. With a commitment to excellence, the European Journal of Preventive Cardiology is an invaluable asset for those dedicated to the prevention of cardiovascular diseases.

Cardiovascular Therapeutics is a renowned Open Access journal, published by WILEY-HINDAWI, that has been at the forefront of advancing knowledge in the field of cardiology and cardiovascular medicine since its establishment. With a strong commitment to disseminating high-quality research, the journal has successfully positioned itself within the Q2 quartile in multiple categories, including Cardiology and Cardiovascular Medicine, Medicine (miscellaneous), and Pharmacology. The journal is indexed in Scopus, achieving impressive rankings, such as #95 out of 387 in Cardiology, and #87 out of 272 in Medical Pharmacology. Situated in the United Kingdom, Cardiovascular Therapeutics embraces an Open Access model since 2019, ensuring that groundbreaking research is accessible to researchers, practitioners, and students across the globe. The journal is dedicated to publishing original research articles, reviews, and clinical studies that contribute to the understanding and treatment of cardiovascular diseases, making it an essential resource for those invested in improving patient outcomes and advancing therapeutic strategies in this vital area of medicine.

COR ET VASA is a prominent peer-reviewed journal in the field of cardiology and cardiovascular medicine, published by the Czech Society of Cardiology and Czech Society of Cardiovascular Surgery. Established in 1961, and continuing its legacy from 2006 to 2024, this journal serves as an essential platform for disseminating significant research findings, clinical studies, and innovative treatments in cardiovascular health. While currently positioned in the Q4 quartile, the journal aims to enhance its impact by fostering knowledge sharing among researchers, clinicians, and students alike. The journal, with its publication in Czech Republic, provides a unique perspective to the European cardiovascular community, allowing for invaluable insights and discourse. Researchers are encouraged to submit their manuscripts and contribute to the growing body of knowledge in this critical area, although it should be noted that COR ET VASA does not offer open access options at this time. As the field of cardiovascular medicine evolves, COR ET VASA remains committed to addressing the latest challenges and advancements, nurturing a rich dialogue within the community.